Loading...

Home
ETF
FBIO

FBIO

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

FBIO News

Fortress Biotech Sells Priority Review Voucher for $205 Million

Feb 23 2026stocktwits

Cyprium Sells Rare Disease Priority Review Voucher for $205 Million

Feb 23 2026Newsfilter

Cyprium Sells Rare Disease Priority Review Voucher for $205 Million

Feb 23 2026Newsfilter

FORTRESS BIOTECH INC - CYPRIUM TO REMIT 20% OF PRV SALE REVENUE TO NIH INSTITUTE

Feb 23 2026moomoo

Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes

Jan 16 2026NASDAQ.COM

FDA Approves ZYCUBO for Menkes Disease, Cyprium to Earn Up to $129M in Milestones

Jan 13 2026stocktwits

Fortress Biotech (FBIO) Secures FDA Approval for ZYCUBO, First Treatment for Menkes Disease

Jan 13 2026NASDAQ.COM

Fortress Biotech's Subsidiary Nears Key FDA Decision, Shares Rise 3%

Jan 13 2026NASDAQ.COM

FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention

Jan 13 2026NASDAQ.COM

Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO

Dec 20 2025NASDAQ.COM

Fortress Biotech's CUTX-101 NDA Resubmission Accepted by FDA with Target Date of January 14, 2026

Dec 15 2025Globenewswire

Fortress Biotech's CUTX-101 NDA Resubmission Accepted by FDA with Target Date of January 14, 2026

Dec 15 2025Newsfilter

Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference

Oct 24 2025Newsfilter

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

Oct 23 2025PRnewswire

Fortress Biotech and Subsidiary Urica Therapeutics Report First Patient Doses in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for Gout Treatment

Oct 21 2025Newsfilter

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

Oct 08 2025PRnewswire